NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.50 Consensus Price Target from Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.50.

Several brokerages recently issued reports on NEO. Piper Sandler boosted their price objective on NeoGenomics from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Monday, February 26th. William Blair restated an “outperform” rating on shares of NeoGenomics in a report on Wednesday, February 21st. The Goldman Sachs Group upped their target price on shares of NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. TD Cowen lowered their target price on NeoGenomics from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Friday, December 29th. Finally, BTIG Research cut their price target on NeoGenomics from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Friday, December 29th.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 2,587 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total transaction of $38,701.52. Following the transaction, the general counsel now owns 34,866 shares of the company’s stock, valued at approximately $521,595.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NEO. Quadrant Capital Group LLC grew its holdings in NeoGenomics by 22.0% during the fourth quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after purchasing an additional 883 shares during the period. Banque Cantonale Vaudoise boosted its stake in shares of NeoGenomics by 6.6% during the 1st quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock worth $251,000 after acquiring an additional 993 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of NeoGenomics by 7.0% during the 4th quarter. Handelsbanken Fonder AB now owns 19,900 shares of the medical research company’s stock worth $322,000 after acquiring an additional 1,300 shares during the last quarter. Yousif Capital Management LLC raised its stake in NeoGenomics by 2.6% in the 4th quarter. Yousif Capital Management LLC now owns 65,447 shares of the medical research company’s stock valued at $1,059,000 after acquiring an additional 1,654 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in NeoGenomics by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 1,791 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Stock Performance

Shares of NASDAQ NEO opened at $13.85 on Friday. The firm has a 50 day moving average price of $15.04 and a 200 day moving average price of $15.88. The company has a debt-to-equity ratio of 0.57, a quick ratio of 5.95 and a current ratio of 6.20. NeoGenomics has a 52-week low of $11.03 and a 52-week high of $21.22.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.05. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. The firm had revenue of $155.55 million for the quarter, compared to analyst estimates of $152.90 million. On average, sell-side analysts forecast that NeoGenomics will post -0.2 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.